Adding Lenalidomide to R-CHOP No Help in High-Risk DLBCL

(MedPage Today) -- Adding an immunomodulator to standard R-CHOP therapy failed to improve progression-free survival in high-risk diffuse large B-cell lymphoma (DLBCL), an international randomized trial showed.
Although median progression-free...